Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CFO Kevin Patrick Moran sold 42,442 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,995.34. Following the sale, the chief financial officer owned 411,380 shares of the company’s stock, valued at $3,402,112.60. The trade was a 9.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vanda Pharmaceuticals Trading Up 4.6%

Shares of VNDA stock traded up $0.36 during trading hours on Wednesday, reaching $8.20. The company’s stock had a trading volume of 1,262,325 shares, compared to its average volume of 4,505,636. The firm’s 50 day simple moving average is $7.56 and its 200-day simple moving average is $5.97. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The company had revenue of $57.22 million during the quarter, compared to the consensus estimate of $59.28 million. As a group, research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Wall Street Analyst Weigh In

VNDA has been the subject of a number of recent analyst reports. B. Riley Financial increased their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, December 31st. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. Zacks Research lowered shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th. Finally, HC Wainwright boosted their target price on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $14.13.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Torren Management LLC acquired a new position in Vanda Pharmaceuticals during the 4th quarter valued at about $25,000. Bailard Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 16.2% in the second quarter. Bailard Inc. now owns 26,100 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 3,631 shares in the last quarter. Panagora Asset Management Inc. boosted its position in shares of Vanda Pharmaceuticals by 3.4% during the fourth quarter. Panagora Asset Management Inc. now owns 118,987 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 3,928 shares during the last quarter. Jane Street Group LLC grew its holdings in Vanda Pharmaceuticals by 6.1% during the second quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 4,533 shares in the last quarter. Finally, Savant Capital LLC raised its position in Vanda Pharmaceuticals by 30.3% in the 3rd quarter. Savant Capital LLC now owns 22,493 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 5,229 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Trending Headlines about Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA grants a formal evidentiary public hearing for Vanda’s sNDA for HETLIOZ (tasimelteon) in jet lag disorder — described as a landmark action and the first drug approval hearing in over 40 years. This raises the chance for public review and could materially affect approval timing and outcome. PR Newswire
• Positive Sentiment: HC Wainwright maintains a Buy view with a $24 price target and issued updated quarterly EPS forecasts for FY2027 (Q1–Q4 estimates provided). The firm’s constructive outlook and high price target support upside sentiment despite near-term losses. MarketBeat VNDA
• Neutral Sentiment: Technical/volume and valuation context — the stock is trading above its 50-day and 200-day moving averages, market cap is roughly $485M and the company remains loss-making (negative P/E). Current intraday volume is below the 3-month average, which may mute short-term moves. MarketBeat VNDA
• Negative Sentiment: Significant insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and two SVPs (Gunther Birznieks and Timothy Williams) each sold large blocks on March 2 (each sale ~30k–156k shares, representing single-digit percentage reductions in their holdings). Multiple high-level executive sales can be perceived negatively by investors and may pressure sentiment even if sales are for diversification or tax reasons. Relevant SEC filings: CEO (Read More.), CFO (Read More.), CMO (Read More.), SVP Gunther Birznieks (Read More.), SVP Timothy Williams (Read More.).

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.